Rutgers, Albert Einstein Medical Schools Launch Carrashield Study

Rutgers, Albert Einstein Medical Schools Launch Carrashield Study

ORLANDO, Fla. — CarraShield Labs, Inc. reported today that Rutgers University New Jersey Medical School and Albert Einstein College of Medicine are performing a National Cancer Institute-funded study on blocking the transmission of the human papillomavirus (HPV) from person to person using Divine 9 personal lubricant.

Divine 9 is made with a formulation of natural seaweed extracts called CarraShield. According to the company, Divine 9 with CarraShield has been shown in previous in vitro (laboratory) and in vivo (mouse) studies conducted by the National Cancer Institute to act as an HPV blocking agent.

Funded through a grant by the National Cancer Institute, the Rutgers and Einstein study is a combined clinical trial and translational research project to determine if CarraShield protects against HPV. One hundred sexually active women are being recruited and then are randomly assigned to receive either Divine 9 with CarraShield as a blocking agent or an ordinary personal lubricant as a placebo. Both the Divine 9 and placebo lubricants are packaged in single-use applicators. The women are asked to use an applicator before, during or within 12 hours after a sexual encounter. Each participant is tested monthly for a wide range of HPV types to determine if CarraShield is able to protect against acquiring new HPV infections.

The principal investigator for the study is Dr. Mark Einstein, Chair of the Department of OB/GYN & Women’s Health and Assistant Dean of the Clinical Research Unit at Rutgers New Jersey Medical School. In 2015, Dr. Einstein launched the initial study on CarraShield at the Albert Einstein College of Medicine (AECOM) in conjunction with the Montefiore Medical Center in New York City. Dr. Einstein is collaborating with a group of experts from AECOM including Robert Burk, M.D., Vice Chair for Translational Research and Professor of Pediatrics, and Professor of Microbiology & Immunology, of Obstetrics & Gynecology and Women’s Health, and of Epidemiology & Population Health. Dr. Burk is an expert on detecting and characterizing HPV in clinical samples.

According to the World Health Organization (WHO), HPV is the cause of essentially all cervical cancers (>99 percent) and cervical cancer is the second most common cancer in women worldwide by age-standardized incidence rate. More than 85 percent of cervical cancer deaths are in developing countries, where it accounts for 13 percent of all female cancers. WHO also estimates that HPV causes 90 percent of anal cancer cases. In a separate study on HPV and throat cancer, AECOM found that the presence of an HPV type in the mouth increases the odds of developing head and neck cancer by 22 times. HPV is also the underlying cause of all genital warts.

Current approaches to HPV prevention have limitations. Most adults are not able to benefit because they are approved only for those aged 26 and younger. The vaccines can also be too expensive for widespread distribution in developing countries.

“People around the world need an accessible and affordable way to protect themselves from the misery and heartache that HPV infections can cause,” said Dean Fresonke, CEO of CarraShield Labs. “With a successful outcome from this study, we will have made significant progress toward an entirely new approach to helping prevent cervical cancer, genital warts and the other health issues caused by HPV.”

For more information, contact Jeff Hawkins at (310) 720-0215 or via email at jeff@carrashieldlabs.com.

Related:  

Copyright © 2026 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

Orion Debuts 'Ride On 2' Vibepad

Orion Wholesale has introduced its new Ride On 2 vibepad.

Report: TDR Capital Reaches $460M Deal to Acquire Lovehoney Group

Private equity firm TDR Capital has reached an agreement to acquire Lovehoney Group in a deal valued at approximately €400 million ($460 million), according to a report by Sky News.

Wild Brands to Unveil 1st Product Collection at XBIZ Expo

Sexual wellness company Wild Brands will introduce its debut product collection at XBIZ Expo in January.

EngErotics Launches Capital Raise Through Campaign on CataCap

Sexual wellness brand EngErotics has launched a campaign to raise capital for expansion on the CataCap philanthropic investment platform.

PinkCherry Relaunches Wholesale Division

Pleasure distributor PinkCherry has relaunched its wholesale division.

Beisar Introduces 'PhoenixGP' Unicorn-Inspired Thrusting Vibe

Beisar has debuted its new PhoenixGP unicorn-spired thrusting, vibrating dildo.

XBIZ 2027 Host Hotel Sold Out, Nearby Room Block Added

and gain an insider look at the latest trends shaping the future of the adult industry.For the upcoming edition, XBIZ Media will host its lineup under one roof, culminating with the 2027 XMAs, the Adult Industry's Biggest Night®.To book a room at Hotel Figueroa, click here.

Orion Adds New Stocking Styles to 'Cottelli Legwear' Line

Orion Wholesale has expanded its Cottelli Legwear collection with several new stocking styles.

Xgen Expands 'Bare by Baci' Wellness Collection

Xgen Products has expanded its Bare by Baci line of wellness products with five new additions, comprising two pleasure balms, two body glow lotions, and a pheromone-infused body mist.

Full Circle Expands 'Be Savage' Lingerie Line

Full Circle has added 77 new items to its Be Savage lingerie collection.

Show More